Polyglandular Autoimmune Syndrome Type 1 (APS-1)

Polyglandular autoimmune syndrome type 1 (APS-1)—also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)—is a rare, inherited immune-system disease caused by harmful changes in the AIRE gene. Because AIRE helps the thymus teach developing T-cells to ignore the body’s own tissues, AIRE malfunction breaks immune tolerance and allows many organ-specific autoimmune attacks. The classic “triad” that raises early suspicion is: chronic mucocutaneous candidiasis (repeated yeast infections of mouth/skin/nails), chronic hypoparathyroidism (low calcium due to parathyroid failure), and primary adrenal insufficiency (Addison disease). Other organs can also be targeted (e.g., thyroid, liver, gut, eyes, skin, and reproductive glands). APS-1 is usually autosomal recessive, can begin in childhood, and often needs lifelong, multi-specialty care with regular screening to catch new components early. MedlinePlus+3NCBI+3NCBI+3

Polyglandular autoimmune syndrome type 1 (APS-1), also called APECED, is a rare, lifelong genetic disease. It happens when a gene called AIRE does not work properly. AIRE’s normal job is to teach the immune system not to attack the body’s own organs. When AIRE is faulty, the immune system can damage several glands and tissues. The classic “triad” is chronic skin and mouth yeast infections (candidiasis), low parathyroid hormone causing low calcium (hypoparathyroidism), and adrenal gland failure (Addison’s disease). Many people also develop problems with teeth enamel, nails, skin, liver, eyes, stomach, and other glands. APS-1 is usually inherited in an autosomal recessive way (both copies of the gene are changed). Diagnosis is made by finding AIRE mutations and/or autoantibodies to type I interferons (e.g., IFN-ω), which are highly specific for APS-1. Management focuses on careful, life-long replacement of missing hormones, prevention and treatment of yeast infections, and monitoring for other autoimmune problems. RUPress+3NCBI+3NCBI+3

The AIRE gene enables the thymus to “show” many body proteins to young T-cells; those that react strongly are deleted—this is immune education. In APS-1, faulty AIRE means some auto-reactive T-cells escape and later attack different organs. Many patients also develop circulating autoantibodies to cytokines like type I interferons and IL-17/IL-22; anti-IL-17/IL-22 weakens mucosal defenses and helps explain the persistent Candida infections, while anti-interferon antibodies are useful for diagnosis. The exact organs affected and order of appearance vary by person, so structured, life-long surveillance is essential. ScienceDirect+3Frontiers+3PMC+3

Polyglandular Autoimmune Syndrome Type 1 (APS-1) is a rare inherited disease in which the body’s immune system, because of a single gene problem called AIRE, does not learn to “tolerate” the body’s own tissues. As a result, immune cells attack several glands and some non-gland organs over time. The classic early signs are (1) chronic mucocutaneous candidiasis (repeated fungal infections of the mouth, skin, or nails), (2) hypoparathyroidism (low parathyroid hormone causing low calcium), and (3) Addison disease (adrenal failure). Most patients develop two of these early; the third often appears later. NCBI+2NCBI+2

---

Other names

• APECED: Autoimmune PolyEndocrinopathy–Candidiasis–Ectodermal Dystrophy

• Autoimmune polyendocrine syndrome type 1, APS-1, APS type 1

• Autoimmune hypoparathyroidism–chronic candidiasis–Addison disease (triad label) NCBI+2Orpha.net+2

---

Types

1) “Classic” APS-1 (APECED). Childhood-onset or early adolescent onset with the triad: chronic mucocutaneous candidiasis, hypoparathyroidism, and Addison disease. Additional autoimmune features accumulate over the years (e.g., enamel hypoplasia, alopecia, vitiligo, pernicious anemia, autoimmune hepatitis, ovarian/testicular failure). Oxford Academic+1

2) Incomplete / atypical APS-1. Some patients first show only one feature (e.g., isolated hypoparathyroidism or only candidiasis) for years, or they present in adulthood. Interferon-autoantibodies and genetic testing for AIRE help unmask these cases. Oxford Academic+1

3) AIRE-variant spectra (including dominant-negative AIRE). Although classic APS-1 is autosomal recessive, rare dominant AIRE variants can produce milder, later, or different constellations of autoimmunity. This widens the clinical spectrum beyond the classic triad. Cell+1

4) APS family of disorders (context). APS-1 is distinct from APS-2/APS-3 (polygenic, adult-onset combinations such as Addison with thyroid disease and/or type 1 diabetes), but recognizing the family helps clinicians anticipate associated problems. NCBI+1

---

Causes

Because APS-1 is monogenic, “causes” mainly means the gene defect plus modifiers that shape who gets what and when.

1. AIRE loss-of-function mutations (autosomal recessive). The fundamental cause that breaks central immune tolerance. PMC+1

2. Failure of thymic “promiscuous” expression of tissue antigens. Fewer organ-specific proteins are shown to developing T-cells, so self-reactive cells survive. PMC+1

3. Escape of autoreactive T-cells to the periphery. These cells later infiltrate endocrine and non-endocrine organs and cause damage. Frontiers

4. Neutralizing autoantibodies to type I interferons. Highly specific for APS-1 and central to immune dysregulation. NCBI

5. Autoantibodies to IL-17A/IL-17F/IL-22. They blunt antifungal mucosal immunity and predispose to chronic Candida infection. RUPress+1

6. Founder mutations and population clusters. Certain AIRE variants are enriched in Finnish, Sardinian, Iranian-Jewish and other populations, increasing local risk. Oxford Academic

7. Consanguinity (recessive inheritance). Increases the chance of two pathogenic AIRE alleles. National Organization for Rare Disorders

8. Genetic modifiers beyond AIRE. Other immune genes (e.g., HLA background) can shape organ targets and disease severity. Oxford Academic

9. Breakdown of thymic medullary epithelial cell function. AIRE-dependent defects in these cells disrupt negative selection. Frontiers

10. Deficient Th17 and Th22 pathways. Low IL-17/IL-22 responses are tied to mucosal candidiasis. JA Community+1

11. Broad autoreactive B-cell responses. Proteome-wide surveys show wide autoantibody repertoires. Nature

12. Endocrine organ-specific autoantibodies (e.g., 21-hydroxylase for adrenals; NALP5/parathyroid). These mark and mediate gland damage. NCBI

13. Mucocutaneous microbiome shifts in the setting of cytokine autoantibodies. Frontiers

14. Environmental triggers (intercurrent infections or stress) may unmask endocrine failure in a vulnerable host. (Inference consistent with APS literature). NCBI

15. Epigenetic influences on immune tolerance genes may modulate expression and penetrance. (Review-based inference). Lippincott Journals

16. Age-related accumulation of targets. More organs tend to be affected as patients age. Oxford Academic

17. Sex-hormone milieu may influence ovarian failure and other targets in females. Frontiers

18. Barrier/ectodermal defects (enamel hypoplasia, nail dystrophy) are part of the syndrome and may amplify mucosal infections. Frontiers

19. Cytokine network imbalance (excess IFN-γ activity with low IL-17/IL-22) favors chronic Candida. ScienceDirect

20. Rare dominant-negative AIRE variants can cause APS-1–like autoimmunity without classic recessive inheritance. Cell

---

Common symptoms and signs

1. Chronic thrush or Candida skin/nail infections. Recurrent, persistent mouth soreness, white plaques, angular cheilitis, nail changes, or skin rashes from Candida. Driven by IL-17/IL-22 pathway autoimmunity. PMC

2. Muscle cramps, tingling, or carpopedal spasm from low calcium due to hypoparathyroidism; may cause seizures in severe cases. NCBI

3. Fatigue, weight loss, dizziness, or darkening of skin from Addison disease (adrenal failure). Dizziness on standing is common. NCBI

4. Tooth-enamel problems (enamel hypoplasia) and early dental decay, often noted in childhood. Frontiers

5. Alopecia (patchy or total hair loss) and vitiligo (light patches of skin) due to autoimmune attack on hair follicles or pigment cells. Frontiers

6. Dry mouth and eye irritation from autoimmune involvement of salivary and lacrimal glands. Frontiers

7. Stomach problems (autoimmune gastritis) leading to vitamin B12 deficiency and anemia. Nature

8. Chronic diarrhea or malabsorption, sometimes due to autoimmune enteropathy or pancreatic involvement. Frontiers

9. Hepatitis (autoimmune liver inflammation) with fatigue, jaundice, or abnormal liver tests. Oxford Academic

10. Ovarian failure (in females) leading to missed periods and infertility; testicular involvement (in males) is rarer. Nature

11. Thyroid disease (less common than in APS-2), sometimes causing hypothyroid symptoms like cold intolerance and constipation. NCBI

12. Type 1 diabetes (some patients), with thirst, frequent urination, and weight loss. NCBI

13. Lung involvement (autoimmune pneumonitis) causing cough or breathlessness in a subset. Frontiers

14. Keratitis or eye surface inflammation with pain or light sensitivity. Oxford Academic

15. General tendency to develop multiple autoimmune diseases over years, often in a stepwise fashion from childhood into adulthood. Oxford Academic

---

Diagnostic tests

A) Physical examination

1. Oral and skin exam for Candida. Look for white curd-like plaques that scrape off, fissures at mouth corners, and intertrigo; nails may be dystrophic. NCBI

2. Skin color and blood pressure check for Addison signs: hyperpigmentation (especially creases), low blood pressure, and weight loss. NCBI

3. Neuromuscular irritability due to hypocalcemia: spontaneous twitching, cramps, or tetany. NCBI

4. Hair, nails, and dental inspection for alopecia, nail dystrophy, and enamel hypoplasia. Frontiers

5. Growth and puberty assessment in children, since chronic endocrine problems can stunt growth and delay puberty. Frontiers

B) Manual (bedside) test

6. Trousseau sign. Inflate a blood-pressure cuff above systolic pressure for 3–5 minutes; carpal spasm indicates latent tetany from hypocalcemia. NCBI

7. Chvostek sign. Tap the facial nerve anterior to the ear; twitching indicates neuromuscular excitability from low calcium. NCBI

8. Orthostatic vitals. Measure pulse and BP lying and standing; a significant drop suggests adrenal insufficiency volume depletion. NCBI

9. Hair-pull test for active alopecia areata activity (multiple hairs extracted with gentle traction). Frontiers

C) Laboratory & pathological tests

10. Serum calcium, phosphorus, magnesium, and intact PTH. Low calcium with low or inappropriately normal PTH confirms hypoparathyroidism. NCBI

11. Morning cortisol and ACTH plus cosyntropin stimulation test to confirm primary adrenal insufficiency. NCBI

12. Autoantibodies to type I interferons (IFN-α/IFN-ω). Highly sensitive and specific; often positive even before full triad appears. NCBI+1

13. Cytokine autoantibodies (IL-17A/IL-17F/IL-22). Support the link to chronic candidiasis. RUPress+1

14. Organ-specific autoantibodies: 21-hydroxylase (adrenal), NALP5 (parathyroid), intrinsic factor/parietal cell (gastritis/B12), TPO/Tg (thyroid), GAD-65/IA-2 (pancreas). Helps stage risk. NCBI

15. Thyroid function tests (TSH, free T4) to detect thyroid involvement. NCBI

16. Glucose/HbA1c to screen for type 1 diabetes; add islet autoantibodies if suspicious. NCBI

17. Fungal microscopy/culture or PCR from oral swab or nail for Candida confirmation when needed. PMC

D) Electrodiagnostic tests

18. ECG to check QT prolongation in hypocalcemia and rhythm problems during crises. NCBI

19. EEG if seizures occur from severe hypocalcemia; helps document cortical irritability and guide care. NCBI

E) Imaging (2)

20. Adrenal imaging (CT/MRI) only when indicated (e.g., if atypical features suggest infection, hemorrhage, or tumor); APS-1 adrenal failure is usually autoimmune and does not need imaging for diagnosis. Bone density (DXA) may be considered over time because chronic hypocalcemia and endocrine disease affect bone health. NCBI

Non-pharmacological treatments (therapies & others)

(Each includes description, purpose, and mechanism—in concise form for readability. All should be applied alongside regular endocrine and infectious-disease care.)

1. Structured lifelong surveillance plan — Set a calendar for periodic checks (calcium/PTH, cortisol/ACTH, thyroid, liver, glucose, B12, celiac screen, eye/dental, skin, growth/puberty in children). Purpose: early detection of new components. Mechanism: earlier identification prevents crises and allows timely treatment. NCBI+1

2. Sick-day rules education — Teach how to increase glucocorticoid dosing during fever, vomiting, or procedures; carry emergency steroid card/bracelet. Purpose: prevent adrenal crisis. Mechanism: anticipatory stress-dosing offsets cortisol deficiency during illness. Endocrine Society+1

3. Emergency action plan — Keep injectable hydrocortisone kit and instructions for family/school; know when to go to ER. Purpose: immediate life-saving response. Mechanism: rapid cortisol replacement during crisis. Endocrine Society

4. Oral/dental hygiene program — Daily toothbrushing, flossing, denture disinfection if used, fluoride varnish, regular dental visits. Purpose: reduce thrush and enamel damage. Mechanism: lowers Candida burden and caries risk in CMC/ectodermal changes. Medscape+1

5. Skin and nail care — Keep skin dry in folds, change sweaty clothing, treat fissures quickly, avoid harsh occlusion. Purpose: reduce fungal overgrowth. Mechanism: moisture control and barrier care suppress Candida colonization. Frontiers

6. Dietary calcium optimization (with clinician guidance) — Spread calcium intake through the day; adequate magnesium; moderate phosphorus. Purpose: steady calcium for hypoparathyroidism. Mechanism: dietary support complements calcitriol/calcium therapy to maintain target calcium. PMC+1

7. Hydration routines — Regular fluid intake, especially during heat/fever; watch for dehydration with diarrhea/vomiting. Purpose: reduce risk of adrenal crisis and kidney stones (from calcium therapy). Mechanism: supports blood pressure/volume and renal calcium handling. PMC+1

8. Salt-adequate diet (if advised with mineralocorticoid therapy) — Don’t restrict salt unless told; some patients need more. Purpose: support fludrocortisone effect. Mechanism: sodium helps maintain volume and blood pressure in primary adrenal insufficiency. Endocrine Society

9. Vaccination per national schedule — Keep routine vaccines current; discuss timing around significant immunosuppression if used for associated hepatitis/other autoimmunity. Purpose: prevent infections that can precipitate crises. Mechanism: immune priming lowers risk of severe illness. NCBI

10. Hand and respiratory hygiene — Especially during community outbreaks. Purpose: prevent intercurrent infections that destabilize endocrine control. Mechanism: reduces exposure load. NCBI

11. Sun/UV & lip protection — Use sunscreen and lip balm to reduce fissures and secondary Candida colonization on damaged skin/lips. Purpose: keep barriers healthy. Mechanism: preserves skin/mucosal integrity. Frontiers

12. Speech/swallow therapy referral (as needed) — For severe oral candidiasis or esophageal involvement affecting feeding. Purpose: maintain nutrition and safe swallowing. Mechanism: compensatory strategies and exercises. PMC

13. Nutrition counseling — Adequate protein, fruits/vegetables, calcium-rich foods; monitor oxalate if high calcium doses; limit excess phosphorus sodas. Purpose: support bone/teeth and metabolic stability. Mechanism: aligns intake with therapy goals. PMC

14. Psychological support — Chronic rare disease care can be stressful; counseling improves coping and adherence. Purpose: quality of life. Mechanism: cognitive-behavioral tools reduce anxiety and improve self-management. NCBI

15. Genetic counseling for family — Explain inheritance (autosomal recessive), testing options, and sibling screening. Purpose: inform family planning and early detection. Mechanism: risk calculation and cascade testing. MedlinePlus

16. Fertility and pregnancy planning — Pre-conception review of hormone replacement and calcium targets; close monitoring if pregnant. Purpose: maternal/fetal safety. Mechanism: adjust glucocorticoid/mineralocorticoid and calcitriol/calcium dosing as physiology changes. Endocrine Society+1

17. Medication interaction checks — Azoles, PPIs, diuretics, and thyroid tablets can interact with endocrine or antifungal therapy. Purpose: avoid dangerous hypo/hyper-states. Mechanism: pharmacist/endocrine review of regimen. PMC

18. Oral appliance and denture care — Nightly cleaning and antifungal soak when advised. Purpose: reduce Candida reservoirs. Mechanism: lowers biofilm on appliances. Medscape

19. Eye care — Baseline and periodic ophthalmology if dry eye, keratitis, or ocular surface disease. Purpose: preserve vision. Mechanism: early lubricants/anti-inflammatory therapy. NCBI

20. Lifestyle rhythm — Regular sleep, gentle exercise as tolerated, stress-management; schedule labs consistently (same time of day). Purpose: smoother hormone day-to-day control. Mechanism: reduces variability in cortisol needs and calcium balance. PMC

---

Drug treatments

(Doses are typical adult starting ranges; pediatric dosing and individual adjustments differ—follow your clinician’s plan.)

1. Hydrocortisone (glucocorticoid). Dose/time: ~15–25 mg/day divided 2–3 doses; increase during illness (“sick-day rules”). Purpose: replace cortisol in Addison disease. Mechanism: restores basal/stress cortisol. Side effects: weight gain, glucose rise, osteoporosis if over-replaced. PMC

2. Fludrocortisone (mineralocorticoid). Dose: 0.05–0.2 mg/day. Purpose: replace aldosterone to maintain salt/water balance. Mechanism: sodium retention, potassium excretion. Side effects: edema, hypertension, hypokalemia. Endocrine Society

3. Emergency hydrocortisone injection (100 mg IM/IV). Use: adrenal crisis or severe illness. Purpose/mechanism: rapid cortisol. Side effects: transient hyperglycemia, mood changes. PMC

4. Levothyroxine (thyroid hormone). Dose: ~1.6 µg/kg/day; adjust to TSH/FT4 when thyroiditis develops. Purpose: treat hypothyroidism component. Mechanism: replaces T4. Side effects: over-replacement causes palpitations, bone loss. NCBI

5. Calcitriol (active vitamin D). Dose: 0.25–2.0 µg/day (divided). Purpose: treat hypoparathyroidism by raising calcium absorption. Mechanism: increases intestinal calcium/phosphate absorption. Side effects: hypercalcemia, hypercalciuria. PMC

6. Elemental calcium (e.g., calcium carbonate/citrate). Dose: often 500–1000 mg 2–3×/day with meals. Purpose: maintain target serum calcium. Mechanism: provides substrate; works with calcitriol. Side effects: constipation, kidney stones if excessive. PMC

7. Thiazide diuretic (e.g., hydrochlorothiazide 12.5–50 mg/day). Purpose: reduce urinary calcium if hypercalciuria on therapy. Mechanism: increases distal tubular calcium reabsorption. Side effects: hyponatremia, hypokalemia, hypotension. Council of Cooperative Health Insurance

8. Fluconazole (azole antifungal). Dose: oropharyngeal candidiasis 200 mg day 1, then 100 mg daily 1–2 weeks; for recurrent CMC, clinicians may use longer or suppressive regimens. Purpose: treat/prevent Candida episodes. Mechanism: inhibits fungal ergosterol synthesis. Side effects: liver enzyme rise, QT prolongation, drug interactions. Medscape Reference+1

9. Nystatin oral suspension. Dose: swish/swallow 4×/day 1–2 weeks. Purpose: mild oral thrush. Mechanism: binds ergosterol; topical effect. Side effects: GI upset. Medscape

10. Clotrimazole troches. Dose: 10 mg 5×/day 1–2 weeks. Purpose: local antifungal. Mechanism: ergosterol synthesis inhibition. Side effects: mouth irritation, interactions minimal. Medscape

11. Itraconazole solution. Dose: 200 mg daily up to 4 weeks if fluconazole-refractory. Purpose: resistant CMC. Mechanism: ergosterol pathway inhibition. Side effects: hepatotoxicity, interactions, negative inotropy. Medscape

12. Posaconazole (selected refractory cases). Purpose: broader azole option when others fail. Mechanism/dose: per specialist protocols. Side effects: QT prolongation, interactions. PMC

13. Echinocandins (e.g., caspofungin, micafungin) for severe/systemic Candida when indicated. Purpose: salvage or systemic therapy. Mechanism: inhibits β-glucan synthesis (cell wall). Side effects: infusion reactions, liver enzyme rise. PMC

14. Azathioprine for APECED-associated autoimmune hepatitis. Dose: individualized (often ~1–2 mg/kg/day) with/without steroids. Purpose: control hepatic autoimmune inflammation. Mechanism: purine antagonist reducing lymphocyte proliferation. Side effects: myelosuppression, infection risk, hepatotoxicity. PMC

15. Prednisone/budesonide (for autoimmune hepatitis or other severe inflammatory components). Purpose: induction of remission. Mechanism: broad anti-inflammatory effects. Side effects: Cushingoid features, glucose rise, bone loss; careful balancing with adrenal replacement. PMC

16. Rituximab (selected severe B-cell–mediated components, off-label). Purpose: deplete B-cells producing

17. Insulin (if type 1 diabetes occurs) – Class. Hormone replacement. Dose. Individualized basal-bolus. Purpose. Control glucose if pancreatic autoimmunity develops. Mechanism. Replaces insulin. Side effects. Hypoglycemia risk. NCBI

18. Proton-pump inhibitor (if severe esophagitis) – Class. Acid suppression. Dose. Standard daily dosing. Purpose. Symptom relief, mucosal healing with candidal esophagitis complications alongside antifungals. Mechanism. Lowers gastric acid to protect mucosa. Side effects. Long-term use risks; use only when indicated. Frontiers

19. Recombinant human PTH (where available/appropriate) – Class. Parathyroid hormone analog. Dose. Specialist use; aim to reduce calcium/calcitriol dependence in selected hypoparathyroidism. Purpose. Physiologic replacement of PTH. Mechanism. Improves renal calcium handling and bone turnover. Side effects. Hypercalcemia/hypercalciuria; access varies (product availability/recalls). Oxford Academic

20. Echinocandins (e.g., micafungin) for resistant Candida – Class. β-glucan synthesis inhibitors. Dose. IV, specialist use for recalcitrant infections. Purpose. Rescue therapy. Mechanism. Weakens fungal cell wall. Side effects. Liver enzyme changes, infusion reactions. Frontiers

Dietary molecular supplements

Always coordinate supplements with your clinician to avoid interactions (especially with azoles, thyroid pills, and calcium).

1) Calcium (citrate preferred with low stomach acid)
Dose. Commonly 500–1500 mg elemental/day in divided doses with meals. Function. Core replacement for low calcium due to hypoparathyroidism. Mechanism. Directly raises serum calcium; citrate form absorbs well and may lower kidney stone risk in some settings. Oxford Academic

2) Active vitamin D (calcitriol)
Dose. 0.25–2.0 µg/day divided; titrate to targets. Function. Enables gut calcium uptake when PTH is low. Mechanism. Bypasses renal activation step to increase intestinal calcium absorption. PMC

3) Vitamin D3 (cholecalciferol)
Dose. Often 1000–2000 IU/day (or as labs dictate). Function. Maintains sufficient 25-OH vitamin D stores. Mechanism. Provides substrate for vitamin D pathways supporting bone and muscle. PMC

4) Magnesium (glycinate or citrate forms)
Dose. 200–400 mg elemental/day as tolerated. Function. Helps stabilize neuromuscular symptoms and supports PTH function. Mechanism. Corrects magnesium deficiency that worsens hypocalcemia. PMC

5) Vitamin B12 (if pernicious anemia)
Dose. Typical 1000 µg IM monthly or high-dose oral if appropriate. Function. Restores red cell production and nerve function. Mechanism. Replaces intrinsic-factor-dependent absorption failure from autoimmune gastritis. NCBI

6) Iron (if iron-deficiency anemia)
Dose. Per labs (e.g., 45–65 mg elemental once or bid). Function. Rebuilds iron stores for hemoglobin. Mechanism. Supplies iron for erythropoiesis when intake/absorption is low. NCBI

7) Selenium (if autoimmune thyroiditis present)
Dose. Often 100–200 µg/day short-term. Function. Supports thyroid antioxidant enzymes. Mechanism. Cofactor for glutathione peroxidases; evidence modest—use selectively. NCBI

8) Omega-3 fatty acids
Dose. ~1 g/day EPA+DHA (food or capsules) if no contraindications. Function. Anti-inflammatory support for general autoimmune burden. Mechanism. Competes with arachidonic acid pathways to reduce inflammatory mediators. NCBI

9) Probiotics (adjunct only)
Dose. Product-specific (short courses). Function. May help oral/GI microbiome balance during/after antifungals; evidence variable. Mechanism. Competitive inhibition and barrier support. Frontiers

10) Vitamin K2 (selected cases)
Dose. Low-dose MK-7 as advised. Function. May support calcium handling when on chronic calcium/vitamin D; evidence evolving. Mechanism. Activates osteocalcin; use only if clinician recommends and labs are monitored. PMC

---

Immunity-booster / regenerative / stem-cell” drugs

Important: There is no approved stem-cell cure for APS-1. Because AIRE acts in thymic epithelial cells, standard bone-marrow transplants generally do not correct the core tolerance defect. The following are specialist, case-by-case immunomodulators—not routine therapy.

1) Intravenous immunoglobulin (IVIG)
Dose. ~1–2 g/kg per cycle. Function. Modulates severe autoimmunity (e.g., neurologic/ocular) in selected cases. Mechanism. Fc-receptor blockade, anti-idiotype effects. PubMed

2) Rituximab
Dose. Protocol-based. Function. For refractory antibody-mediated complications. Mechanism. B-cell depletion (anti-CD20). PubMed

3) Mycophenolate mofetil
Dose. 1–2 g/day. Function. Steroid-sparing control of difficult organ autoimmunity. Mechanism. Inhibits lymphocyte purine synthesis. PubMed

4) Azathioprine
Dose. ~1–2 mg/kg/day. Function. Maintenance after steroid induction for autoimmune hepatitis or other organ autoimmunity. Mechanism. Purine analog immunosuppression. NCBI

5) Abatacept (select cases)
Dose. Weight-based IV/SC. Function. Considered in refractory T-cell–driven autoimmunity (case-report level). Mechanism. CTLA-4-Ig blocks costimulation. PubMed

6) HSCT (hematopoietic stem-cell transplant) — generally not recommended
Dose. N/A. Function. Not standard for APS-1 because it does not fix thymic AIRE expression. Mechanism. Replaces immune cells but not the AIRE-defective thymic epithelium. NCBI

---

Surgeries/procedures

1) Dental restorative procedures (sealants, composites, crowns)
Why. To repair enamel hypoplasia and prevent decay/pain. Evidence. Dental involvement is common due to ectodermal changes in APS-1. NCBI

2) Ophthalmic procedures (amniotic membrane graft/surface reconstruction)
Why. For severe keratopathy unresponsive to drops/lenses to protect vision. NCBI

3) Esophageal dilation (endoscopic)
Why. Very rarely, strictures from chronic esophagitis require dilation for swallowing. Frontiers

4) Liver biopsy
Why. To confirm autoimmune hepatitis and stage disease before immunosuppression. NCBI

5) Central line/port (exceptional cases)
Why. For recurrent IV therapies (e.g., parenteral nutrition or IV antifungals) when absolutely necessary. Note. Risks usually outweigh benefits; used sparingly. Frontiers

---

Preventions

1. Keep vaccinations current (discuss schedule with your team). Oxford Academic

2. Follow sick-day rules for Addison’s and carry emergency hydrocortisone. Oxford Academic

3. Oral/skin hygiene to reduce Candida relapse. Frontiers

4. Regular labs to detect new issues early (calcium, urine calcium, cortisol/ACTH at risk times, thyroid, liver, B12). PMC+1

5. Medication timing: separate calcium from levothyroxine and some antibiotics/azoles to avoid interactions. Oxford Academic

6. Hydration and low-oxalate diet if urine calcium is high. PMC

7. Sun protection and emollients for skin barrier care. NCBI

8. Eye lubrication and protective eyewear in harsh environments. NCBI

9. Dental fluoride and check-ups every 3–6 months. NCBI

10. Genetic counseling for family awareness and early screening. NCBI

---

When to see a doctor

• Immediately/ER: Severe vomiting/diarrhea with Addison’s (cannot keep pills down), fainting, extreme weakness, confusion, severe abdominal pain, very low blood pressure—use emergency hydrocortisone and call for help. Oxford Academic

• Urgently: New muscle cramps, tingling around mouth/fingers, seizures (possible hypocalcemia), high fever, spreading skin rash, painful mouth sores not improving. PMC

• Soon/clinic: More frequent thrush/skin infections, new eye irritation or light sensitivity, darkening skin, salt craving, weight loss, prolonged fatigue, hair loss, brittle nails, dental pain, abdominal discomfort, yellowing eyes/skin (possible liver involvement). NCBI

---

What to eat / what to avoid

• Eat:

1. Calcium-rich foods (as advised) spread across meals. Oxford Academic

2. Adequate protein for tissue repair and immune health. NCBI

3. Magnesium-rich foods (greens, nuts, legumes). PMC

4. Hydration: water evenly through the day (kidney health). PMC

5. B12/iron sources if deficient (pernicious anemia). NCBI

• Avoid/Limit:

6. Very high-oxalate foods if urine calcium is high (spinach, rhubarb, nuts in excess). PMC

7. Alcohol/tobacco (worsen bone and liver health). NCBI

8. Grapefruit juice with certain medicines (azole/other interactions). Frontiers

9. Excessive caffeine (diuretic; can affect calcium balance). PMC

10. Sugary snacks that feed oral Candida; choose sugar-free options. Frontiers

---

FAQs

1) Is APS-1 the same as APS-2?
No. APS-1/APECED is due to AIRE mutations and usually begins in childhood; APS-2 is a different, more common adult autoimmune clustering. NCBI

2) What is the “classic triad”?
Chronic Candida infections, hypoparathyroidism, and Addison’s disease. NCBI

3) Why so much Candida?
Many patients have autoantibodies to IL-17 and IL-22, blocking antifungal defenses. PMC+1

4) How is it diagnosed?
Clinical features plus AIRE testing and autoantibodies (especially anti-type I interferons). NCBI

5) Is it inherited?
Usually autosomal recessive—both parents carry one changed copy. NCBI

6) What is the long-term outlook?
With hormone replacement, antifungal care, and regular screening, many live well; risks are adrenal crisis and complications from untreated components. Oxford Academic

7) Do I need lifelong medicines?
Yes—replacements like hydrocortisone, fludrocortisone, calcium/calcitriol are typically lifelong once those glands fail. Oxford Academic+1

8) Can it affect the liver or stomach?
Yes—autoimmune hepatitis and pernicious anemia can occur; monitoring is important. NCBI

9) Are there special blood tests?
Yes—anti-IFN-ω/α and sometimes anti-IL-17/IL-22 are characteristic; they support the diagnosis. RUPress

10) Do I need an emergency plan?
Absolutely—sick-day rules, IM hydrocortisone, medical ID. Oxford Academic

11) What about pregnancy?
Plan with specialists; adjust hormone doses and antifungal strategies safely. Oxford Academic

12) Are stem cells a cure?
No proven cure; HSCT usually doesn’t fix AIRE-related thymic defects. NCBI

13) Could I get thyroid or diabetes problems?
Yes, other autoimmune gland problems can appear; regular screening helps early treatment. NCBI

14) Why do I need dental and eye checks?
APS-1 often affects enamel and ocular surfaces; early care prevents pain and vision loss. NCBI

15) Where can I read more?
Endotext APS chapter; Frontiers in Pediatrics AIRE review; J Exp Med/J Clin Immunol papers on IL-17/IL-22 autoantibodies; endocrine society guidelines for hypoparathyroidism and adrenal insufficiency. Oxford Academic+4NCBI+4Frontiers+4

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 29, 2025.

PDF Documents For This Disease Condition References